Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

Core Insights - Portage Biotech has resumed patient enrollment in the final cohort of the dose escalation stage for PORT-6, a selective A2A antagonist, within its ADPORT-601 Phase 1b clinical trial, following a previous pause due to funding concerns [1][2] - The resumption of the trial indicates encouraging findings from earlier cohorts, reinforcing the company's confidence in the safety and therapeutic potential of PORT-6 [2][3] - The planned co-administration of PORT-6 and PORT-7, a selective A2B antagonist, aims to achieve a complete blockade of adenosine-induced immunosuppression in the tumor microenvironment, enhancing anti-tumor responses [3] Company Overview - Portage Biotech is a clinical-stage immuno-oncology company focused on advancing a pipeline of novel biologics to enhance the immune system's ability to combat cancer [4]